NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site

#3523

Introduction: G3 NENs are aggressive tumors with limited treatment options. Prognosis is rather poor even with best available platinum-based CT (OS of 11m).

Aim(s): To assess safety and efficacy of CT plus nivolumab in untreated patients (pts) with advanced G3 NENs.

Materials and methods: NICENEC (GETNE-T1913) is a non-randomized, open-label, phase II trial that recruited 38 pts with metastatic or locally advanced unresectable G3 NENs of GEP/UK origin. Pts received Nivolumab 360mg d1, Carboplatin AUC 5 d1, Etoposide 100mg/m2/d d1-3 Q3W (up to 6 cycles) followed by Nivolumab 480mg Q4W (up to 24 m). Primary endpoint was 12mOS rate.

Conference:

Presenting Author:

Authors: Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teulé A,

Keywords: Grade 3 Neuroendocrine Neoplasm, nivolumab, gastroenteropancreatic,